Abstract
Nucleobindin-2 is a 420 amino acid EF-hand Ca2+ binding protein that can be further processed to generate an 82 amino terminal peptide termed Nesfatin-1. To examine the function of secreted Nucleobindin-2 in adipocyte differentiation, cultured 3T3-L1 cells were incubated with either 0 or 100 nM of GST, GST-Nucleobindin-2, prior to and during the initiation of adipocyte differentiation. Nucleobindin-2 treatment decreased neutral lipid accumulation (Oil-Red O staining) and expression of several marker genes for adipocyte differentiation (PPARγ, aP2, and adipsin). When Nucleobindin- 2 was constitutively secreted into cultured medium, cAMP content and insulin stimulated CREB phosphorylation were significantly reduced. On the other hand, intracellularly overexpressed Nucleobindin-2 failed to affect cAMP content and CREB phosphorylation. Taken together, these data indicate that secreted Nucleobindin-2 is a suppressor of adipocyte differentiation through inhibition of cAMP production and insulin signal.
Keywords: Nucleobindin-2, Nesfatin-1, adipogenesis, 3T3-L1, insulin, GST
Protein & Peptide Letters
Title:Secreted Nucleobindin-2 Inhibits 3T3-L1 Adipocyte Differentiation
Volume: 19 Issue: 9
Author(s): Yuko Tagaya, Aya Osaki, Atsuko Miura, Shuichi Okada, Kihachi Ohshima, Koshi Hashimoto, Masanobu Yamada, Tetsurou Satoh, Hiroyuki Shimizu and Masatomo Mori
Affiliation:
Keywords: Nucleobindin-2, Nesfatin-1, adipogenesis, 3T3-L1, insulin, GST
Abstract: Nucleobindin-2 is a 420 amino acid EF-hand Ca2+ binding protein that can be further processed to generate an 82 amino terminal peptide termed Nesfatin-1. To examine the function of secreted Nucleobindin-2 in adipocyte differentiation, cultured 3T3-L1 cells were incubated with either 0 or 100 nM of GST, GST-Nucleobindin-2, prior to and during the initiation of adipocyte differentiation. Nucleobindin-2 treatment decreased neutral lipid accumulation (Oil-Red O staining) and expression of several marker genes for adipocyte differentiation (PPARγ, aP2, and adipsin). When Nucleobindin- 2 was constitutively secreted into cultured medium, cAMP content and insulin stimulated CREB phosphorylation were significantly reduced. On the other hand, intracellularly overexpressed Nucleobindin-2 failed to affect cAMP content and CREB phosphorylation. Taken together, these data indicate that secreted Nucleobindin-2 is a suppressor of adipocyte differentiation through inhibition of cAMP production and insulin signal.
Export Options
About this article
Cite this article as:
Tagaya Yuko, Osaki Aya, Miura Atsuko, Okada Shuichi, Ohshima Kihachi, Hashimoto Koshi, Yamada Masanobu, Satoh Tetsurou, Shimizu Hiroyuki and Mori Masatomo, Secreted Nucleobindin-2 Inhibits 3T3-L1 Adipocyte Differentiation, Protein & Peptide Letters 2012; 19 (9) . https://dx.doi.org/10.2174/092986612802084546
DOI https://dx.doi.org/10.2174/092986612802084546 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Association Serum S100B Protein in Alzheimer’s Disease: A Case Control Study from South India
Current Alzheimer Research Common Genetic Conditions of Ischemic Stroke to Keep in Mind
Current Molecular Medicine Review on Characteristics and Analytical Methods of Remogliflozin Etabonate: An Update
Mini-Reviews in Medicinal Chemistry Electroporation Advances in Large Animals
Current Gene Therapy EDITORIAL [Hot topic: Tissue Fibrosis (Guest Editor: Shizuya Saika)]
Endocrine, Metabolic & Immune Disorders - Drug Targets Peptides as Carrier for Tumor Diagnosis and Treatment
Current Medicinal Chemistry - Anti-Cancer Agents Emerging Roles for Riboflavin in Functional Rescue of Mitochondrial β-Oxidation Flavoenzymes
Current Medicinal Chemistry A New Bone Marrow Transplantation Method for the Prevention of Graft- Versus-Host Disease
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Lafora Progressive Myoclonus Epilepsy: Recent Insights into Cell Degeneration
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Reciprocal Interactions Between Wakefulness and Sleep Influence Global and Regional Brain Activity
Current Topics in Medicinal Chemistry Signal Peptides - Promising Ingredients in Cosmetics
Current Protein & Peptide Science Disorder in Milk Proteins: α -Lactalbumin. Part A. Structural Properties and Conformational Behavior
Current Protein & Peptide Science Gene Polymorphism of Angiotensin II Type 1 and Type 2 Receptors
Current Pharmaceutical Design The Epidemiology of Cardiovascular Disease in Adults with Type 1 Diabetes
Current Diabetes Reviews Medullary Thyroid Cancer: New Targeted Molecular Therapies
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Immunological Aspects of the Prostate Gland and Related Diseases
Current Immunology Reviews (Discontinued) Screening for Genetic Mutations. A Review
Combinatorial Chemistry & High Throughput Screening Tumor Necrosis Factor-a Blockade in Rheumatoid Arthritis: Responders Vs Non Responders
Medicinal Chemistry Reviews - Online (Discontinued) Structural Analysis As an Alternative to Identify and Determine Mode of Action of Antimicrobial Peptides: Proposition of a Kinetic Model Based on Molecular Dynamics Studies
Protein & Peptide Letters Hypertension and Diabetes: Emphasis on the Renin – Angiotensin System and Insulin Resistance
Current Hypertension Reviews